Department of Hematology

1. Principal Investigator: “Deciphering the role of Bone Marrow Mesenchymal Stem Cell derived Exosomes in the Pathobiology of Aplastic anemia", by DBT, Govt. of India, New Delhi, 2019-2022, Rs 62, 40, 000/-.

2. Principal Investigator: “Evaluation of cardiomyogenic potential of Ckit+ human amniotic fluid mesenchymal stem cells”, by Science and Engineering Board, Dept of Science and Technology, Govt of India, New Delhi, 2019-2022, Rs 49, 59 360.

3. Principal Investigator:“Evaluation of renogenic properties of amniotic fluid stem cells and their therapeutic efficacy in acute renal failure” ”, by Dept. of Biotechnology (DBT), Govt. of India, New Delhi, 2017- 2019, Rs 39,00, 000

4. Principal Investigator: “Mesenchymal stem cells in myocardial infarction, stroke, renal failure and diabetes: Program Support Project, granted under establishment of “Specialized Center for Cell-based Therapy”, by Dept. of Biotechnology (DBT), Govt. of India, New Delhi, 2005-2014, Rs 4, 16, 79, 700

5. Principal Investigator: Indo Denmark bilateral collaboration entitled, “Characterization of different sub-populations of human Mesenchymal stem cells and evaluation of their therapeutic efficacy in myocardial regeneration” DBT, Govt. of India, New Delhi, 2007-2013, Rs. 2, 53, 01, 000

6. Co-Investigator:“Intravenous Autologous Bone Marrow - Derived Stem Cell Therapy for Patients with Acute Ischemic Stroke”, DBT, Govt. of India, New Delhi, 2008-2011, Rs 41,36, 500

7. Principal Investigator – “Efficacy of stem cells in improvement of left ventricular function in patients with acute myocardial infarction”, DBT, Govt. of India, New Delhi, 2007-2011, Rs. 55, 29, 600

8. Principal Investigator- “Stem cells for regenerative medicine: Isolation of Multipotent adult progenitor cells and their clonal expansion and differentiation into cardiomyocytes, hepatocytes and islet cells, DBT, Govt. of India, New Delhi, 2005-2011, Rs 44, 56, 000

9. Principal Investigator – “Role of αβ and γδ T-cells in Takayasu’s arteritis”, ICMR, Govt. of India, New Delhi, 2003-2006, Rs 17, 00, 000

10. Principal Investigator- “Anti- endothelial cell antibodies (AECA) in Takayasu’s Arteritis; antigenic targets, pathogenecity and specificity”, UPCST, UP Govt., Lucknow, India, 2001-2004, Rs 5, 00, 000.

11. Principal Investigator – “Phase III Randomized Multicentre Comparative Study of Peg interferon -2a vs Roferon-A for the treatment of Patients with Recently Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) not Previously Treated with Interferon”, Sponsored by Hoffman-La Roche Inc, Conducted by Quintiles (CRO), 2001-2003, Rs 15, 00, 000.

12. Principal Investigator – “A study of expanded populations of T lymphocytes in Wegener’s granulomatosis (WG) and Takayasu’s arteritis (TA)”, KI Fond, Karolinska Institute, Stockholm, Sweden, 1998 – 1999, SEK 100, 000.

13. Principal Investigator – “Immunological basis of aplastic anemia”, Indian National Science Academy, New Delhi, India, 1998 –2001, Rs 5, 00, 000.

14. Principal Investigator: “Immunopathogenic mechanisms in Wegener’s Granulomatosis and Takayasu’s arterits, King Gustav the Vs 80 Years Fond, Stockholm, Sweden, 1998 –2000, SEK 100,000.

15. Co-investigator: “Immune mechanisms in premature myocardial infarction and stroke”, King Gustav the Vs. 80 years Fond, Stockholm, Sweden, 1996 – 1998, SEK 100,000.

1. PI: “Strategies for early detection and counseling of Thalassemia carriers”, Approved by National Health Mission, India.

2. Co-I - “Deciphering the role of Bone Marrow Mesenchymal Stem Cell derived Exosomes in the Pathobiology of Aplastic anemia", by DBT, Govt. of India, New Delhi, 2019-2022, Rs 62, 40, 000/-

1. Principle Investigator. Program Implementation proposal (PIP): Strengthening Thalassemia care services in Uttar Pradesh. National Health Mission. Rs 44,00,000/-2019-2022

2. Co-Investigator. Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukaemia in Routine Clinical Practice.Lambda Laboratories Ltd.2016-2021

3. Co-Investigator Deciphering Role of Epigenetic Mechanisms in Normal and Malignant Hematopoiesis. Wellcome Trust DBT India Alliance, Rs 3,60,55,580/-, 2017-2022

1. Pricniple Investigator: Program implementation plan approved by National Health Mission in 2019, for “Strategies towards Comprehensive Hemophilia Care Services in Uttar Pradesh”

1. Co-Investigator: Evaluation of cardiomyogenic potential of cKit+ human amniotic fluid mesenchymal stem cells, SERB, DST, Govt of India, Neew Delhi. 2019-22; Rs 49, 59, 360.

2. Co-Investigator: Indo-Denish bilateral collaborative project entitled, “Characterization of different sub-populations of human Mesenchymal stem cells and evaluation of their therapeutic efficacy in myocardial regeneration”. Funded by: Department of Biotechnology (DBT), Govt. of India; Grant Period: 2007-2010; and Grant Amount: Rs 189, 55, 000/-.

3. Co-Investigator: Multicentric clinical trial entitled “Efficacy of stem cells in improvement of left ventricular function in patients with acute myocardial infarction”. Funded by: DBT, Govt. of India; Grant Period: 2006-2009, and Grant Amount: Rs. 32, 70, 800/-.

4. Co-Investigator: Project for establishment of cell-based therapy entitled “Mesenchymal stem cell therapy in myocardial infarction, stroke, renal failure and diabetes”. Funded By: DBT, Govt. of India; Grant Period: 2005-2010; and Grant amount: Rs 200, 93, 000/-.

5. 5. Co-Investigator: R & D project entitled ‘Stem cells for regenerative medicine: Isolation of Multipotent adult progenitor cells and their clonal expansion and differentiation into cardiomyocytes, hepatocytes and islet cells". Funded by: DBT, Govt. of India; Grant Period Grant Period: 2006-2009; and Grant amount: Rs 45, 56, 000/-.

1. Title: Deciphering Role of Epigenetic Mechanisms in Normal and Malignant Hematopoiesis. Funding agency:Wellcome Trust DBT India Alliance (2017-2022; INR 3,60,55,580/-). [Role-PI]

2. Title:Deciphering Role of epigenetic mechanisms in regulating gene expression program in hematopoiesis. Funding agency:DBT, Govt. of India, Granted under DBT Ramalingaswamy Fellowship Scheme (2013- 2017; INR 65,00,000/-) [Role-PI]

1. Title:Generation and differentiation of footprint free human induced pluripotent stem cells into pancreatic β-cells: A giant leap toward a clinical-grade cell source for diabetes treatment(Funded by DST-SERB, Amount- 3628740lakh).[Role-PI]

2. Title:Generation of Bioengineered Human Pancreatic Organoid Model for Environmental Diabetogens Screening: A step towards targeted therapy for Diabetes (Funded by ICMR, Amount 50.0 Lakh).[Role–PI]

3. Title:Derivation and Navigation of Porcine (SusScrofa) Pluripotent stem cells towards cardiomyocytes (Funding agency-DST, 22.0 lakh).[RolePI]

4. Title:Generation and differentiation of foot print-free goat (Capra hircus) iPSCs into muscle cells: A step forward for test tube meat production (Funded by SERB, New Delhi, amount 47.2 lakh). [Role–PI]

5. Title: Generation of bona fide Bubaline induced pluripotent stem (iPS) cells (Fundingagency-UGC,6.0 lakh). [Role PI]

6. Title: STAT3 and ISL1 mediated regulation of stem cell derived cardiomyocytes (Funded by UPCST, amount -3.75 lakh); CST/ YSS/ D-2873).[Role–PI]

1. Title:Understanding the epigenetic basis of lympho-myeloid switch: An escape mechanism from CD19+CAR T-cell therapy (Funding Agency-ICMR; Amount-50 Lacs). [Role-PI]

2. Title:Understanding the molecular basis of MEF2D-rearranged oncogenic fusion proteins in Leukemogenesis (Funding Agency-DST-SERB; Amount-30 Lacs). [Role-PI]

1. Principle Investigator: “Evaluation of the prevalence of Invasive Aspergillosis and optimal duration of Anti-fungal Therapy in Acute Leukemia patients using Quantitative Galactomannan Antigen and Aspergillus DNA Assays” Intra-mural grant by SGPGIMS, Lucknow, 2019-2021, Rs 5,00, 000

2. Principal Investigator- “Effect of Aplastic Anemia Bone Marrow Mesenchymal Stem Cell derived Extracellular Vesicles on Hematopoietic Stem Cells”, Intra-mural grant by SGPGIMS, Lucknow, 2018-2020, Rs 5, 00, 000.

3. Principal Investigator:“Molecular characteristics including Ikaros 6 isoform expression in Indian acute lymphoblastic leukemia patients Project by SGPGI, Lucknow, 2016-2018 , Rs 4, 90, 000

4. Principal Investigator: “Evaluation of hematopoiesis regulatory molecules in bone marrow mesenchymal stem cells of patients with aplastic anemia”, Intramural Project by SGPGI, Lucknow, 2015-2017, Rs 3, 00, 000

5. Principal Investigator- “A study of the mechanism of induction of apoptosis by ALG”, Intra Mural Grant from SGPGIMS, Lucknow, India, 2000-2001, Rs 1, 25, 000/-

6. Principal Investigator – Does Anti-lymphocyte globulin produce its therapeutic action in aplastic anemia by inducing an apoptysis of lymphocytes”, Intra Mural Grant from SGPGI, Lucknow, India, 1999 – 2000, Rs 1, 25, 000.

7. Principal Investigator: “Characterization of antibodies to endothelial cells of different origins”’ Intra Mural Grant from SGPGI, Lucknow, India, 1997 –1998, Rs 1, 50, 000

8. Principal Investigator – “Anti-endothelial cell antibodies – Prevalence and antigenic determinants”, Intra Mural Grant from SGPGIMS, Luck now, India, 1994 – 1996, Rs 1, 00, 000.

1. Principle Investigator: ‘Role of miRNA in the pathogenesis of aplastic anemia’ (2017-2019) Rs 5,00,000

2. Principle Investigator: ‘Diagnostic and prognostic significance of flow cytometry in Multiple Myeloma”. (2017- 2019). Rs 3,80,000

3. PI: ‘Diagnostic utility of flow cytometry in Myelodysplastic Syndrome” (2014-2016). Rs 2,50,000

4. Co-Investigator: ‘Utility of immunofluorescence using anti PML antibody and multicolor flow cytometry for rapid diagnosis of APML along with their correlation with PCR PML-RARA fusion transcript”. (2014-2016).

5. Co-Investigator: ‘Detection of CALR mutation and MPL mutation in myelo-proliferative neoplasm” (2017-2019)

6. Co-Investigator: ‘Role of Killer Cell Immunoglobulin-like Receptors (KIRs) in Selection of Haploidentical Donors” (2017-2019)

1. Principle Investigator: ‘Evaluation of peripheral blood Dendritic cell subset count as a potential biomarker in classical Hodgkin Lymphoma’. Intramural project. SGPGIMS, Lucknow, India, 2019-2021. ONGOING (INR 4.25 Lacs)

2. Principle Investigator: ‘Evaluation of calreticulin (CALR) & myeloproliferative leukemia virus (MPL) gene mutation profile in myeloproliferative neoplasm and their clinicopathological correlation’. Intramural project. SGPGIMS, Lucknow, India, 2017-2019. COMPLETED (INR4.98 lacs)

3. Principle Investigator: “Utility of immunofluorescence using anti-PML protein antibody and multicolour flow cytometry for Rapid diagnosis of APML along with their correlation with PCR for PML RARA fusion transcript”. Intramural project. SGPGIMS, Lucknow, India, 2014-2017. COMPLETED (INR 3.0 Lacs)

4. Co-Investigator: Role of miRNA in the pathogenesis of acquired aplastic anemia. Intramural project. SGPGIMS, Lucknow, India, 2017-2019. COMPLETED

5. Co-investigator: “Diagnostic and prognostic significance of flow cytometry in Multiple Myeloma”. Intramural project. SGPGIMS, Lucknow, India, 2017-2019. COMPLETED

6. Co-investigator – “Role of Killer Cell Immunoglobulin-like Receptors (KIRs) in Selection of Haploidentical Donors” Intramural project. SGPGIMS, Lucknow, India, 2017-2019. COMPLETED

7. Co Investigator: Frequency and significance of IKAROS mutation in Acute Lymphoblastic leukaemia. Intramural project. SGPGIMS, Lucknow, India, 2016-2018. COMPLETED

8. Co-investigator: “Evaluation of hematopoiesis regulatory molecules in bone marrow mesenchymal stem cells of patients with aplastic anemia”. Intramural project. SGPGIMS, Lucknow, India, 2014-2017 COMPLETED

9. Co-investigator: Flow cytometric evaluation of Myelodysplastic syndrome. Intramural project. SGPGIMS, Lucknow, India, 2014-2016 COMPLETED

10. Co-investigator: Minimal residual disease detection in paediatric acute lymphoblastic leukaemia by flow cytometry. Intramural project; RGCIRC, New Delhi. 2012-2014. COMPLETED

1. Principle Investigator. Evaluation of Molecular Mutations and their Correlation with Response to Induction Chemotherapy in Acute Myeloid Leukemia, Intramural Project, SGPGI, Lucknow, Rs.5,00,000/-. 2016-2018

2. Co-Investigator: Molecular characteristics including Ikaros 6 isoform expression in India acute lymphoblastic leukemia patients. Intramural Project, SGPGI, Lucknow. Rs 4,90,000/-2016-2018

3. Co-Investigator: Evaluation of the prevalence of Invasive Aspergillosis and optimal duration of Anti-fungal Therapy in Acute Leukemia patients using Quantitative Galactomannan Antigen and Aspergillus DNA Assays. Co-Investigator. Intramural Project, SGPGI, LucknowRs.5,00,000/-2018-2020

1. Pricniple Investigator: “Role of Killer Cell Immunoglobulin-like Receptors (KIRs) in Selection of Haploidentical Donors”; 2017-2019.

1. Pricniple Investigator: “Diagnostic Utility of ADAMTS-13 Assay and Plasmic Score in Patients of Thrombotic Thrombocytopenic Purpura”; 2020-2022.

2. Co- Investigator: ‘Evaluation of calreticulin (CALR) & myeloproliferative leukemia virus (MPL) gene mutation profile in myeloproliferative neoplasm and their clinicopathological correlation’; 2017-2019.

3. Co-Investigator: “Role of miRNA in the pathogenesis of acquired aplastic anemia”; 2017-2019.

1.Title:Generation of anti-CD19+ Chimeric Antigen Receptor (CD19+ CAR) T-cells and evaluation of cytotoxic efficacy for leukemic cells (Funding Agency-SGPGIMS; Amount- 5 Lacs). [Role-PI]